First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: AptarGroup: the story is balanced — Pharma segment volume growth driven by new drug-device combination product launches and respiratory therapy adoption…
★ Analysts see FY2026 revenue reaching $4.0B — +5.5% growth in a single year.
What Moves the Stock
1Pharma segment volume growth driven by new drug-device combination product launches and respiratory therapy adoption (inhalers, nasal sprays)
2Beauty segment demand tied to prestige cosmetics and fragrance market health, particularly in Europe and Asia-Pacific
3Raw material cost inflation (polypropylene, elastomers, aluminum) and ability to pass through pricing to customers
4New product innovation pipeline, particularly in active material science (preservative-free formulations) and sustainable packaging solutions
5M&A activity targeting bolt-on acquisitions in injectables or digital health dispensing technologies
6Pharma segment (~50% of revenue): Metered-dose inhalers, nasal spray pumps, injectable delivery systems, active material science solutions for biologics
7Beauty + Home segment (~40% of revenue): Dispensing pumps for cosmetics, fragrance, personal care, and household products
8Food + Beverage segment (~10% of revenue): Closures and dispensing systems for food, beverage, and nutrition markets
quality growth - Attracts investors seeking durable competitive advantages through regulatory moats and customer switching costs…
Rising interest rates create modest headwinds through higher financing costs on the company's $1.5B debt load (Debt/Equity of 0.57)…
Watch on earnings: Polypropylene resin spot prices (primary raw material for pumps and closures, ~20% of COGS), Global pharmaceutical R&D spending and new drug approval rates (leading indicator for drug delivery device demand), Prestige beauty market growth rates in US, Europe, and China (Estée Lauder, L'Oréal quarterly results as proxies).
One Sentence Summary:
AptarGroup: the story is balanced — pharma segment volume growth driven by new drug-device combination product launches and respiratory therapy adoption (inhalers.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.